Tilray CEO Says Schedule III Marks A Turning Point For U.S. Medical Cannabis

The Trump administration’s decision to reclassify state‑legal medical cannabis as a Schedule III substance marks the most significant shift in federal marijuana policy in decades. The April 23 order signals a federal acknowledgment that medical cannabis has therapeutic value and should be regulated within a healthcare framework rather than treated like Schedule I substances.

The change arrives at a moment when the industry’s largest players are already navigating a complex global landscape. Tilray, one of the world’s biggest cannabis companies, operates medical and adult‑use businesses across more than 20 countries. The company reported revenue of about $207 million in its most recent quarter and roughly $11 million in adjusted EBITDA, driven in part by strong international medical cannabis growth. That scale and experience give Tilray a unique vantage point as the United States begins to reshape its federal approach to medical cannabis.

While the long‑term implications of Schedule III remain uncertain, the shift introduces new expectations. Companies that want to benefit from rescheduling will need to prepare for a more structured regulatory environment. Operators will face new requirements around quality, consistency, compliance, and data that go far beyond today’s state‑based systems.

Tilray Chairman and CEO Irwin Simon says the shift aligns with the direction his company has been building toward for years. In a written interview, he outlined how rescheduling changes the landscape for medical cannabis and why companies with pharmaceutical‑grade infrastructure will be best positioned to lead.

A New Federal Baseline For Medical Cannabis

Simon said the rescheduling order is an important validation of medical cannabis, but he cautioned that it does not instantly create a national medical market. He framed the decision as a meaningful step that begins to move cannabis into the healthcare system.

“I view the April 23 rescheduling order as a meaningful and long‑overdue validation of medical cannabis, but it’s important to be clear: it does not create a fully formed U.S. medical market overnight,” Irwin said.

He added that the immediate impact is on credibility and opportunities, particularly in research, regulatory engagement, and physician confidence. But he emphasized that commercial participation at scale will depend on the federal frameworks that come next.

Higher Standards And A More Demanding Operating Model

When asked how Schedule III will affect companies already operating in state markets, Simon said the shift will require operators to elevate their systems to pharmaceutical‑level standards. He noted that the change will separate companies that can meet those expectations from those that cannot.

“Schedule III shifts federal medical cannabis regulations in the U.S. towards a pharmaceutical framework, and that fundamentally changes the operating model,” said Simon. 

He pointed to requirements such as validated manufacturing processes, GMP compliance, batch consistency, traceability, and audit readiness. According to Simon, these expectations mirror the standards Tilray already follows in Europe and other regulated medical markets.

Integrating Cannabis Into Mainstream Healthcare

Simon said rescheduling will gradually bring medical cannabis into the broader healthcare system, improving patient access, physician participation, and eventually insurance engagement. He described the shift as a long‑term evolution rather than an immediate transformation.

“Rescheduling is the catalyst that begins to integrate medical cannabis into the mainstream healthcare system, and over the next several years, that shift has the potential to be transformative,” Simon explained.

He said standardized products, clinical data, and regulatory clarity will help physicians feel more confident prescribing cannabis. Over time, he expects insurance reimbursement to become possible as the category matures and outcomes are validated.

Tilray’s Strategy Remains Focused On A Federal Medical Model

Simon notes the regulatory shift does not change Tilray’s U.S. strategy. Instead, it reinforces the company’s long‑standing focus on a federally anchored medical market rather than a state‑by‑state retail approach.

“This shift reinforces the strategy we have been building toward,” he said. “It does not change it.”

Simon added that Tilray plans to bring its global medical capabilities to the U.S. as federal agencies develop a more structured framework. That includes clinical research experience, proprietary genetics, and pharmaceutical‑grade production.

Positioning For Pharmaceutical Channels And Clinical Development

Schedule III opens new opportunities in pharmaceutical distribution, clinical trials, and federally regulated pathways. Simon emphasized that companies with established medical infrastructure will have a clear advantage as the market evolves.

“Schedule III moves cannabis into a framework that rewards science, consistency, and compliance,’ he explained. “That plays directly to Tilray’s strengths.”

He noted that Tilray already operates EU‑GMP certified facilities and distributes medical cannabis through pharmacy networks internationally. As the U.S. moves toward a more standardized system, he expects that experience to translate into a competitive edge.

Looking Ahead

Taken together, Simon’s comments outline a future in which medical cannabis is shaped by pharmaceutical standards, clinical rigor, and federal oversight. Rescheduling may not create an immediate national market, but it sets the stage for a more credible and structured medical system. Companies that have already invested in quality, compliance, and research will be better positioned as federal agencies define the next phase of regulation.

For Tilray, the shift represents an acceleration rather than a pivot. The company expects its global medical platform to align naturally with the direction U.S. regulators are moving. As federal rules take shape, the industry will begin to see which operators can meet the demands of a true medical framework and which will struggle to adapt. The next several years will determine how quickly the U.S. market evolves and which companies are prepared to lead it.